Active Ingredient History
Urelumab is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 1)
Glioblastoma (Phase 1)
Gliosarcoma (Phase 1)
Head and Neck Neoplasms (Phase 1)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 2)
Skin Neoplasms (Early Phase 1)
Urinary Bladder Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue